Lixte Biotechnology Hldgs Inc SEC Filings

Lixte Biotechnology CEO Geordan Garrett Pursglove restructured his equity compensation on April 15, 2026. He agreed to cancel 350,000 options to purchase common stock with a $2.83 exercise price that were scheduled to expire on July 3, 2030, returning them to the company.

In exchange, he received 350,000 shares of common stock as a grant or award tied to 350,000 restricted share units under the 2020 Stock Incentive Plan. These RSUs vest immediately upon grant, so he now directly holds 350,000 common shares after the transaction. The filing shows no open‑market buying or selling; it is an issuer disposition of options paired with a compensatory stock award.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Chief Financial Officer Peter Stazzone restructured his equity compensation on April 15, 2026. He agreed to cancel 50,000 stock options with a $4.45 exercise price in exchange for 50,000 restricted stock units granted the same day.

Each RSU represents a contingent right to receive one share of common stock, and all 50,000 RSUs vested immediately upon grant, leaving him with 50,000 shares of common stock held directly after the transactions. No open‑market buying or selling occurred; these were compensation-related adjustments between the executive and the company.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Chief Financial Officer Peter Stazzone restructured his equity compensation on April 15, 2026. He agreed to cancel 50,000 stock options with a $4.45 exercise price in exchange for 50,000 restricted stock units granted the same day.

Each RSU represents a contingent right to receive one share of common stock, and all 50,000 RSUs vested immediately upon grant, leaving him with 50,000 shares of common stock held directly after the transactions. No open‑market buying or selling occurred; these were compensation-related adjustments between the executive and the company.

Director Jason David Sawyer reported a compensation-related change in his equity awards in LIXTE BIOTECHNOLOGY HOLDINGS, INC. On April 15, 2026, he agreed with the company to cancel 25,000 options to purchase common stock with a $3.59 exercise price, which otherwise would have vested over time. In exchange, he received 25,000 restricted share units (RSUs), each representing a contingent right to one share of common stock. The RSUs were granted under the company’s 2020 Stock Incentive Plan and vested immediately upon grant, resulting in 25,000 shares of common stock held directly after the transactions. This sequence is a restructuring of equity compensation rather than an open-market buy or sell.

Director Jason David Sawyer reported a compensation-related change in his equity awards in LIXTE BIOTECHNOLOGY HOLDINGS, INC. On April 15, 2026, he agreed with the company to cancel 25,000 options to purchase common stock with a $3.59 exercise price, which otherwise would have vested over time. In exchange, he received 25,000 restricted share units (RSUs), each representing a contingent right to one share of common stock. The RSUs were granted under the company’s 2020 Stock Incentive Plan and vested immediately upon grant, resulting in 25,000 shares of common stock held directly after the transactions. This sequence is a restructuring of equity compensation rather than an open-market buy or sell.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Felix Lourdes entered into a Stock Option Cancellation Agreement on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price that had been granted on December 24, 2025 and, in exchange, granted 25,000 restricted share units (RSUs).

Each RSU represents a right to receive one share of common stock upon vesting, and all 25,000 RSUs vested immediately on the grant date. Following these compensation-related transactions, Lourdes directly holds 25,000 shares of common stock, with no remaining options from the canceled grant.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Felix Lourdes entered into a Stock Option Cancellation Agreement on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price that had been granted on December 24, 2025 and, in exchange, granted 25,000 restricted share units (RSUs).

Each RSU represents a right to receive one share of common stock upon vesting, and all 25,000 RSUs vested immediately on the grant date. Following these compensation-related transactions, Lourdes directly holds 25,000 shares of common stock, with no remaining options from the canceled grant.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Guy Warren Primus exchanged equity awards on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price and, under a Stock Option Cancellation Agreement, granted 25,000 restricted share units that vest immediately, giving him 25,000 shares of common stock directly owned after the transaction.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Guy Warren Primus exchanged equity awards on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price and, under a Stock Option Cancellation Agreement, granted 25,000 restricted share units that vest immediately, giving him 25,000 shares of common stock directly owned after the transaction.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Michael Andrew Holloway restructured his equity compensation on April 15, 2026. He disposed of options to purchase 25,000 shares of common stock back to the company and, in exchange, received 25,000 restricted share units (RSUs).

Each RSU represents a right to receive one share of common stock, and all 25,000 RSUs vested immediately upon grant, subject to continued service conditions in the plan documents. Following these transactions, Holloway directly holds 25,000 shares of common stock, reflecting this grant-and-cancel structure rather than an open-market trade.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Michael Andrew Holloway restructured his equity compensation on April 15, 2026. He disposed of options to purchase 25,000 shares of common stock back to the company and, in exchange, received 25,000 restricted share units (RSUs).

Each RSU represents a right to receive one share of common stock, and all 25,000 RSUs vested immediately upon grant, subject to continued service conditions in the plan documents. Following these transactions, Holloway directly holds 25,000 shares of common stock, reflecting this grant-and-cancel structure rather than an open-market trade.

Lixte Biotechnology Holdings reports itself as a clinical-stage cancer company with no product revenue, expanding from its LB-100 drug platform into proton therapy through majority ownership of Liora Technologies Europe.

The company recorded a net loss of $6,009,520 for 2025 versus $3,585,965 in 2024 and an accumulated deficit of $58,077,213, and its auditors raised substantial doubt about its ability to continue as a going concern. Management expects existing cash to fund operations only into late 2026 and plans to raise additional capital by mid‑2026.

LB-100 is being evaluated in multiple oncology trials, including combinations with doxorubicin, PD‑1 and PD‑L1 checkpoint inhibitors in ovarian clear cell carcinoma, metastatic microsatellite-stable colorectal cancer and soft tissue sarcoma, supported by collaborations with MD Anderson, GSK and the Netherlands Cancer Institute. Lixte has decided not to fund the randomized Phase 2 sarcoma trial, avoiding about $3,095,000 in planned costs, and settled a consulting dispute for $100,000. The company highlights an extensive global patent estate around LB‑100, its combinations and prodrugs, and outlines Liora’s LiGHT proton therapy prototype, which targets lower-cost, high-throughput proton treatment and FLASH-capable radiotherapy but will require further investment and regulatory clearance before clinical use.

Lixte Biotechnology Holdings reports itself as a clinical-stage cancer company with no product revenue, expanding from its LB-100 drug platform into proton therapy through majority ownership of Liora Technologies Europe.

The company recorded a net loss of $6,009,520 for 2025 versus $3,585,965 in 2024 and an accumulated deficit of $58,077,213, and its auditors raised substantial doubt about its ability to continue as a going concern. Management expects existing cash to fund operations only into late 2026 and plans to raise additional capital by mid‑2026.

LB-100 is being evaluated in multiple oncology trials, including combinations with doxorubicin, PD‑1 and PD‑L1 checkpoint inhibitors in ovarian clear cell carcinoma, metastatic microsatellite-stable colorectal cancer and soft tissue sarcoma, supported by collaborations with MD Anderson, GSK and the Netherlands Cancer Institute. Lixte has decided not to fund the randomized Phase 2 sarcoma trial, avoiding about $3,095,000 in planned costs, and settled a consulting dispute for $100,000. The company highlights an extensive global patent estate around LB‑100, its combinations and prodrugs, and outlines Liora’s LiGHT proton therapy prototype, which targets lower-cost, high-throughput proton treatment and FLASH-capable radiotherapy but will require further investment and regulatory clearance before clinical use.

Lixte Biotechnology Holdings, Inc. updated its executive compensation by amending the employment agreement of Chief Executive Officer Geordan Pursglove. Effective January 1, 2026, his annual base salary increased from $240,000 to $360,000, as approved by the Compensation Committee and Board of Directors. The salary Amendment, dated March 18, 2026, is filed as Exhibit 10.1 and incorporated by reference into this report.

Lixte Biotechnology Holdings, Inc. updated its executive compensation by amending the employment agreement of Chief Executive Officer Geordan Pursglove. Effective January 1, 2026, his annual base salary increased from $240,000 to $360,000, as approved by the Compensation Committee and Board of Directors. The salary Amendment, dated March 18, 2026, is filed as Exhibit 10.1 and incorporated by reference into this report.

Lixte Biotechnology Holdings entered into an Amended and Restated Share Exchange Agreement with its subsidiary Liora Technologies Europe and Orbit Capital, dated March 6, 2026 and effective as of November 21, 2025. This agreement consolidates prior arrangements into a single structure.

Under earlier agreements, Lixte had acquired 100% of Liora, issued 2,700 shares of Series C Preferred Stock to Orbit and entered a royalty agreement, which was later terminated. Orbit then exchanged those preferred shares for 700,000 shares of Lixte common stock and reacquired a 20% ownership interest in Liora. The new agreement is intended to reflect these combined transactions and the parties’ agreed ownership structure.

Lixte Biotechnology Holdings entered into an Amended and Restated Share Exchange Agreement with its subsidiary Liora Technologies Europe and Orbit Capital, dated March 6, 2026 and effective as of November 21, 2025. This agreement consolidates prior arrangements into a single structure.

Under earlier agreements, Lixte had acquired 100% of Liora, issued 2,700 shares of Series C Preferred Stock to Orbit and entered a royalty agreement, which was later terminated. Orbit then exchanged those preferred shares for 700,000 shares of Lixte common stock and reacquired a 20% ownership interest in Liora. The new agreement is intended to reflect these combined transactions and the parties’ agreed ownership structure.

LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.

Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.

LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.

Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.